Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients ASH: Sarclisa...
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP ASH:...
Communiqué de presse : ASH : le rilzabrutinib a apporté un bénéfice significatif aux patients atteints de TPI dans le cadre de la première étude...
Communiqué de presse : Mise en ligne des états financiers révisés de Sanofi hors Opella Mise en ligne des états financiers révisés de Sanofi hors...
Press Release: Availability of the revised financial statements for Sanofi excluding Opella Availability of the revised financial statements for...
Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for...
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa...
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in...
Communiqué de presse : Dupixent, premier et seul médicament approuvé dans l’UE pour le traitement de l’œsophagite à éosinophiles du jeune enfant...
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong...
Communiqué de presse : T3 2024 : Croissance des ventes de 15,7% soutenue par une séquence des ventes de vaccins plus favorable qu’anticipée;...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관